Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells

Abstract

Metastatic melanoma is the most aggressive skin cancer. Recently, phenotypically distinct subpopulations of tumor cells were identified. Among them, ABCB5-expressing cells were proposed to display an enhanced tumorigenicity with stem cell-like properties. In addition, ABCB5+ cells are thought to participate to chemoresistance through a potential efflux function of ABCB5. Nevertheless, the fate of these cells upon drugs that are used in melanoma chemotherapy remains to be clarified. Here we explored the effect of anti-melanoma treatments on the ABCB5-expressing cells. Using a melanoma xenograft model (WM266-4), we observed in vivo that ABCB5-expressing cells are enriched after a temozolomide treatment that induces a significant tumor regression. These results were further confirmed in a preliminary study conducted on clinical samples from patients that received dacarbazine. In vitro, we showed that ABCB5-expressing cells selectively survive when exposed to dacarbazine, the reference treatment of metastatic melanoma, but also to vemurafenib, a new inhibitor of the mutated kinase V600E BRAF and other various chemotherapeutic drugs. Our results show that anti-melanoma chemotherapy might participate to the chemoresistance acquisition by selecting tumor cell subpopulations expressing ABCB5. This is of particular importance in understanding the relapses observed after anti-melanoma treatments and reinforces the interest of ABCB5 and ABCB5-expressing cells as potential therapeutic targets in melanoma.

Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma

“…As expected for melanoma SCs, live GFP high cells overexpressed ABCB5 and CD271 surface markers, conferring their CSC phenotype [19,20,30], and consistently, TNF significantly (p < 0.01) increased the pool of GFP high-…”

Strategies for Isolating and Enriching Cancer Stem Cells: Well Begun Is Half Done

“…Furthermore, the proportion of CD133-positive cells in U251 glioma cells increases after the administration of rotenone and ethidium bromide [182]. Recent research has revealed that melanoma cells are enriched in ABCB5-expressing cells after temozolomide treatment and that these ABCB5-expressing cells exhibit enhanced tumorigenicity, with SC-like properties [183]. Ionizing radiation can activate stemness pathways in HCC cells and can result in the enrichment of a CSC subpopulation with higher resistance to radiotherapy [184].…”

CD133 + melanoma subpopulation acquired resistance to caffeic acid phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: Significance for melanoma treatment

“…Besides their ability to differentiate into various cell types [9], MSCs have the ability to form "melanoma spheroids" when grown in serum-free medium supplemented with growth factors [10], and exhibit self-renewal activity in vitro [1,11] and tumorigenic potency in vivo [12]. MSCs are also characterized by the expression of stem cell markers including CD20, CD133 [1,9,13], ABCB5 [14], CD166 [1,7], CD146 [15], and Nestin [16]. Also, the elevated expression of Bmi-1 has been reported in MSCs [17].…”